Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2025)

Crinetics Pharmaceuticals has reported Equity Average over the past 8 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Equity Average at $1.0 billion for Q4 2025, down 4.33% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (down 4.33% YoY), and the annual figure for FY2025 was $1.2 billion, up 24.3%.
  • Equity Average for Q4 2025 was $1.0 billion at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Equity Average for CRNX hit a ceiling of $1.3 billion in Q1 2025 and a floor of $159.2 million in Q1 2021.
  • Median Equity Average over the past 5 years was $384.9 million (2022), compared with a mean of $589.8 million.
  • Biggest five-year swings in Equity Average: fell 22.46% in 2023 and later soared 219.15% in 2024.
  • Crinetics Pharmaceuticals' Equity Average stood at $262.8 million in 2021, then rose by 27.05% to $333.8 million in 2022, then skyrocketed by 62.78% to $543.4 million in 2023, then skyrocketed by 98.53% to $1.1 billion in 2024, then decreased by 4.33% to $1.0 billion in 2025.
  • The last three reported values for Equity Average were $1.0 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.